FULC Earnings & Financial Statements
Fulcrum Therapeutics, Inc.
$3.75
+$0.08(+2.18%)
33
Overall
60
Value
10
Tech
31
Quality
Market Cap
$280.01M
Volume
2.63M
52W Range
$2.83 - $15.74
Target Price
$6.40
FULC earnings and financial statements: Fulcrum Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
FULC Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $80.00M | $2.81M | $6.34M | $19.16M |
| Operating income | -$84.77M | -$21.90M | -$110.66M | -$112.56M | -$81.05M |
| EBITDA | -$83.38M | -$20.30M | -$95.16M | -$107.31M | -$78.54M |
| Net income | -$74.88M | -$9.72M | -$97.33M | -$109.87M | -$80.85M |
| EPS (diluted) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $366.28M | $260.72M | $257.69M | $226.69M | $235.00M |
| Total liabilities | $17.28M | $17.68M | $22.50M | $27.74M | $23.46M |
| Shareholders’ equity | $349.00M | $243.03M | $235.19M | $198.94M | $211.54M |
| Cash and equivalents | $197.53M | $58.21M | $25.56M | $35.10M | $35.41M |
| Long-term debt | $4.04M | $6.44M | $8.63M | $10.82M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$60.06M | -$2.22M | -$90.97M | -$97.05M | -$78.48M |
| Capital expenditure | -$314.0K | -$278.0K | -$508.0K | -$1.96M | -$1.71M |
| Free cash flow | -$60.38M | -$2.50M | -$91.47M | -$99.01M | -$80.19M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | FULC | $3.75 | +2.2% | 2.63M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Fulcrum Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW